The new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining?
|
|
|
- Jocelyn Howard
- 6 years ago
- Views:
Transcription
1 S. aureus: what do we need to know (and to do) in 2007? The new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining? Françoise Van Bambeke Unité de Pharmacologie cellulaire et moléculaire Université catholique de Louvain Bruxelles, Belgium Sympo S. aureus 11/01/07-1
2 Sympo S. aureus 11/01/07-2 do we need new drugs?
3 Rice, Am. J. Med. (2006) 119:S11-9 Sympo S. aureus 11/01/07-3 «old» antibiotics: still usable for CA-MRSA!
4 Sabol et al., Ann. Pharmacother. (2006) 40: Sympo S. aureus 11/01/07-4 «old» antibiotics: still usable for CA-MRSA!
5 recent and novel agents for S. aureus recently brought on the Belgian market on the market; not yet in Belgium (late) stage of clinical development investigational moxifloxacin linezolid synercid daptomycin tigecycline telavancin oritavancin dalbavancin CS-023/PZ-601 MX-2401 API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK What will be your choice? Sympo S. aureus 11/01/07-5
6 recent and novel agents for S. aureus recently brought on the Belgian market on the market; not yet in Belgium (late) stage of clinical development investigational moxifloxacin linezolid synercid daptomycin tigecycline telavancin oritavancin dalbavancin CS-023/PZ-601 MX-2401 API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK Let s try to find a way Sympo S. aureus 11/01/07-6
7 recent and novel agents for S. aureus recently brought on the Belgian market on the market; not yet in Belgium (late) stage of clinical development investigational moxifloxacin linezolid synercid daptomycin tigecycline telavancin oritavancin dalbavancin CS-023/PZ-601 MX-2401 API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK Sympo S. aureus 11/01/07-7
8 Kaka et al., JAC (2006) 58:680-3 Sympo S. aureus 11/01/07-8 moxifloxacin and CA-MRSA killing curves - 6 CA-MRSA Δ log CFU/ml clindamycin linezolid minocycline rifampicin sulfametoxazole moxifloxacin time (h) rapidly bactericidal
9 moxifloxacin: in vitro data Distribution of MICs for 100 MRSA collected in 2002 Lowest MICs among currently available quinolones, but percentage of strains breakpoint S R cipro levo moxi MIC (mg/l) Noguchi et al., Int. J. Antimicrob. Ag. (2005) 25:374-9 low level resistance high level resistance Sympo S. aureus 11/01/07-9
10 Sympo S. aureus 11/01/07-10 moxifloxacin: pros and cons rapidly bactericidal easy switch iv-po once-a-day no major toxicity issue (already quite large clinical experience) cross resistance with other quinolones even if MIC lower CA-MRSA only risk of QTc interval (drug interactions!)
11 recent and novel agents for S. aureus recently brought on the Belgian market on the market; not yet in Belgium (late) stage of clinical development investigational moxifloxacin linezolid synercid daptomycin tigecycline telavancin oritavancin dalbavancin CS-023/PZ-601 MX-2401 API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK Sympo S. aureus 11/01/07-11
12 Bozdogan & Appelbaum, Int. J. Antimicrob. Ag. (2004) 23:113-9 Sympo S. aureus 11/01/07-12 linezolid O HN O N N O F O inhibits the formation of the initiation complex no cross resistance with other drugs acting on protein synthesis (MLS) resistance considered for long as improbable but now well described (due to mutations in 23S rrna)
13 Goldstein et al., AAC (2006) 50: Sympo S. aureus 11/01/07-13 linezolid: in vitro data Distribution of MICs for 60 MRSA collected from diabetic foot drug range MIC 50 MIC 90 breakpoint vancomycin linezolid We slowly reach the limit
14 Wilson et al., JAC (2006) 58:470-3 Sympo S. aureus 11/01/07-14 linezolid: in vitro data Susceptibility of MRSA by site of isolation breakpoint 8 4 again we approach the limit
15 linezolid: clinical experience indication Linezolid 600 mg iv/po 2x/day Vancomycin 1g iv 2x/day cssti (1180) 99.2 % 88.5 % Osteomyelitis (66) 84.8 % -- MRSA bacteriaemia (53) 56 % 46 % nosocomial pneumonia (1019) MRSA (160) 53 % 59 % 52.2 % 35.5 % Weigelt et al., AAC (2005) 49: ; Senneville et al., Clin Ther. (2006) 28: ; Shorr et al., JAC (2005) 56: ; Wunderink et al., Chest (2003)124: Sympo S. aureus 11/01/07-15
16 Sympo S. aureus 11/01/07-16 linezolid: pros and cons excellent biodisponibility and tissue penetration easy switch iv-po bacteriostatic resistance already selected high price twice-a-day serious side effects (myelosuppression) drug interactions (IMAO)
17 recent and novel agents for S. aureus recently brought on the Belgian market on the market; not yet in Belgium (late) stage of clinical development investigational moxifloxacin linezolid synercid daptomycin tigecycline telavancin oritavancin dalbavancin CS-023/PZ-601 MX-2401 API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK Sympo S. aureus 11/01/07-17
18 Harms et al., BMB Biol (2004) 2:4 Sympo S. aureus 11/01/07-18 synercid S A blocks peptide bound formation dalfopristin SYNERGY quinupristin S B blocks the path of the nascent peptide
19 Sambatakou et al., JAC (1998) 51: Sympo S. aureus 11/01/07-19 synercid: in vitro data Susceptibility of 101 MRSA percentage of strains breakpoint S R MIC (mg/l) What about these?
20 Baudoux et al., ECCMID (2007) Sympo S. aureus 11/01/07-20 synercid: in vitro data In vitro models - MRSA Δlog CFU from time h 24h MIC Cmax Log concentration (mg/l) time- and concentration-dependent bactericidal effect
21 Allen et al., AAC (2002) 46: Sympo S. aureus 11/01/07-21 synercid: in vitro data In vitro pharmacodynamic models poorly active alone against MRSA; highly active on VRE combinations synergistic towards MRSA
22 Sympo S. aureus 11/01/07-22 synercid : pros and cons highly active on VRE synergistic in vitro with many ABs poorly bactericidal against MRSA bid or tid administration no oral route cross-resistance with ML drug interactions (CYP450 3A4) caution with drugs prolonging QTc myalgia/arthralgia frequent high price not studied in children
23 recent and novel agents for S. aureus recently brought on the Belgian market on the market; not yet in Belgium (late) stage of clinical development investigational moxifloxacin linezolid synercid daptomycin tigecycline telavancin oritavancin dalbavancin CS-023/PZ-601 MX-2401 API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK Sympo S. aureus 11/01/07-23
24 daptomycin very bactericidal towards Gram (+) organisms through membrane destabilization spare mammalian cells because they lack phosphatidylglycerol (critical for binding to Gram(+) membranes) fast track registration in the US because of activity against vancomycin-resistant enterococci (VRE) indications: cssti; Phase III trial on bacteriemia completed Sympo S. aureus 11/01/07-24
25 Goldstein et al., AAC (2006) 50: Sympo S. aureus 11/01/07-25 daptomycin: in vitro data Distribution of MICs for 60 MRSA collected from diabetic foot drug range MIC 50 MIC 90 breakpoint vancomycin daptomycin wait and see
26 daptomycin: clinical experience indication cssti (902) MRSA (28-36) bloodstream (31) MRSA (11) VRE (11) Daptomycin iv 1x/day 4 mg/kg 83.4 % 75 % 6 mg/kg 77 % 100 % 45 % Vancomycin or β-lactam 84.2 % 69.4 % -- Arbeit et al., CID (2004) 38: ; Segreti et al., Pharmacotherapy (2006) 26: Sympo S. aureus 11/01/07-26
27 Sympo S. aureus 11/01/07-27 daptomycin: pros and cons rapidly bactericidal once-a-day inactive in pneumonia VISA tend to have MICs high price no oral route musculotoxic in animals avoid combination with inhibitors of HMGCoA reductase safety / efficacy not studied in < 18 years
28 recent and novel agents for S. aureus recently brought on the Belgian market on the market; not yet in Belgium (late) stage of clinical development investigational moxifloxacin linezolid synercid daptomycin tigecycline telavancin oritavancin dalbavancin CS-023/PZ-601 MX-2401 API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK Sympo S. aureus 11/01/07-28
29 tigecycline tigecycline tetracycline minocycline Olson et al., AAC (2006) 50: same binding site as tetracyclines in ribosome 16S RNA; additional interaction site Unaffected by resistance due to - ribosomal protection - Tet efflux pumps Approved in USA in 2005 and in Europe in 2006 wide spectrum, indicated for: cssti; intra-abdominal infections Sympo S. aureus 11/01/07-29
30 Low et al., Int. J. Antimicrob. Ag. (2002) 20:220-2 Sympo S. aureus 11/01/07-30 tigecycline: in vitro data Distribution of MICs for 128 MRSA from USA breakpoint active on minocycline-r population, but percentage of strains 80 S R tigecycline minocycline MIC (mg/l) a few isolates above the breakpoint
31 Ellis-Grosse et al., Clin. Infect. Dis. (2005) 41:S Sympo S. aureus 11/01/07-31 tigecycline clinical experience Phase 3 - Skin and skin structure infections
32 Sympo S. aureus 11/01/07-32 tigecycline : pros and cons XL spectrum? not affected by some tet resistance mechanisms (Tet efflux, ribosomal protection) once-a-day large tissue distribution XL spectrum? bacteriostatic CI pregnancy, children no oral route
33 recent and novel agents for S. aureus recently brought on the Belgian market on the market; not yet in Belgium (late) stage of clinical development investigational moxifloxacin linezolid synercid daptomycin tigecycline telavancin oritavancin dalbavancin CS-023/PZ-601 MX-2401 API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK Sympo S. aureus 11/01/07-33
34 Van Bambeke, Cur. Opin. Pharmacol. (2004) 4:471-8 Sympo S. aureus 11/01/07-34 new glycopeptides: structure-activity relationship
35 (a) Candiani et al., JAC (1999) 44:179-92; (b) King et al., JAC (2004) 53: Sympo S. aureus 11/01/07-35 new glycopeptides: in vitro data Distribution of MICs for MRSA drug range (a) n = 23 (b) n=30 breakpoint telavancin oritavancin vancomycin dalbavancin MICs of the same range as for vanco, but teicoplanin no breakpoint yet for new GP
36 Sympo S. aureus 11/01/07-36 new glycopeptides: mode of action rapid bactericidal effect, related to multiple modes of action
37 Barcia-Macay et al., JAC (2006) 58: Sympo S. aureus 11/01/07-37 new glycopeptides: mode of action rapid bactericidal effect, related to multiple modes of action Activity of telavancin after 3 h towards S. aureus with different resistance phenotypes Δ log CFU from time 0 3 MRSA MSSA MSSA - vanco log concentration (X MIC) Bimodal effect : inhibition of PG synthesis membrane permeabilization Δ log CFU from time 0 3 VISA VRSA log concentration (X MIC) Unimodal effect : inhibition of PG synthesis membrane permeabilization
38 Van Bambeke, Curr. Opin. Investig. Drugs (2006) 7:740-9 Sympo S. aureus 11/01/07-38 new glycopeptides: clinical experience oritavancin (5-10 mg/kg 1x day ~ 10 days) skin and soft tissue infection (Phase III) bloodstream infection (Phase II) telavancin (10 mg/kg 1x day ~ 10 days) skin and soft tissue infection (Phase III) fast track designation by the FDA for the treatment of hospitally-acquired pneumonia (MRSA or multiresistant S. pneumoniae) MRSA-associated complicated skin and skin structure infection dalbavancin (1 g followed by 500 mg 1 week later) skin and skin structure infections (Phases II and III) catheter-related bloodstream infections (Phase II) priority review status by the FDA for the treatment of MRSA complicated skin and soft tissue infections.
39 Kanafani, Exp. Rev. Anti-inf. Ther. (2006) 4:743-9; Sympo S. aureus 11/01/07-39 new glycopeptides: clinical experience Phase 3 - Skin and skin structure infections
40 Sympo S. aureus 11/01/07-40 new glycopeptides : pros and cons rapidly bactericidal once-a-day / a-week active on VISA and VRSA (not DAL) no oral route once-a-week? prolonged retention in the organism (DAL)?
41 recent and novel agents for S. aureus recently brought on the Belgian market on the market; not yet in Belgium (late) stage of clinical development investigational moxifloxacin linezolid synercid daptomycin tigecycline telavancin oritavancin dalbavancin CS-023/PZ-601 MX-2401 API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK Sympo S. aureus 11/01/07-41
42 Hebeisen et al., AAC (2001) 45: Sympo S. aureus 11/01/07-42 ceftobiprole NH 2 β-lactamases S N N N H N H S PBP2a O prodrug OH O BAL9141 O N HO O O N NH O O O O BAL5788 Capable of binding to PBP2a of MRSA Fast track designation from FDA for cssti and nosocomial pneumonia
43 Sahm et al., ICAAC (2006) E0113 Sympo S. aureus 11/01/07-43 ceftobiprole in vitro data Susceptibility of 1275 MRSA drug range MIC 50 MIC 90 breakpoint vancomycin ceftobiprole * so far, so good, but for how long? * provisional breakpoint Mouton et al, AAC (2004) 48:
44 Noel et al., ICAAC (2006) L1212 Sympo S. aureus 11/01/07-44 Ceftobiprole clinical experience csssi 784 patients
45 Sympo S. aureus 11/01/07-45 ceftobiprole: pros and cons broad spectrum? (polymicrobial infections) bactericidal synergistic with AG tissue penetration broad spectrum? trend to MIC increase iv only twice-a-day
46 a few additional criteria of choice Sympo S. aureus 11/01/07-46
47 what about Belgian isolates? Susceptibility of 511 MRSA from 112 hospitals All isolates still below the breakpoint MIC = breakpoint cumulative percentage of strains /32 1/16 1/8 1/4 1/2 1/1 2/ MIC breakpoint 0.5 ratio 1 2 breakpoint vancomycin ceftobiprole daptomycin synercid tigecycline linezolid but do we agree with all breakpoints? 4 Denis et al., AAC (2006) 50: Sympo S. aureus 11/01/07-47
48 Sympo S. aureus 11/01/07-48 conclusion a lot of molecules in the pipeline synercid: usefulness in Europe? daptomycin: bactericidal, but surfactant effect tigecycline: polymicrobial infections, but static really new still to come new glycopeptides: bactericidal, resistance probably difficult to select FabI inhibitors: totally new target, MICs very low question for the future:
49 Sympo S. aureus 11/01/07-49 Thank you for your attention and happy birthday to Hergé
MRSA treatment: does the future shine? Françoise Van Bambeke & Paul M. Tulkens Unité de Pharmacologie cellulaire et moléculaire.
MRSA treatment: does the future shine? Françoise Van Bambeke & Paul M. Tulkens Unité de Pharmacologie cellulaire et moléculaire UCL - Brussels MRSA : where are there? At home! And here too! Deplano et
Therapeutic options: what s new in the pipeline?
Therapeutic options: what s new in the pipeline? Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology & Centre for Clinical Pharmacy Louvain Drug Research Institute, Université catholique de Louvain,
Activity of antibiotics against extracellular and intracellular forms of Staphylococcus aureus
Maritza Barcia-Macay (Patterson) Unité de Pharmacologie cellulaire et moléculaire Activity of antibiotics against extracellular and intracellular forms of Staphylococcus aureus Pharmacodynamic studies
Appropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
Staph Cases. Case #1
Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling
Le infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
ICAAC. Key words: antibacterial agent development approval. linezolid β. chloramphenicol tetracycline colistin mupirocin teicoplanin
16 11 1 16 11 25 58 238 154 β 65 25 24 20 10 46 10 19 5 10 10 10 ICAAC Key words: antibacterial agent development approval 1946 60 238 10 Fig. 1 β 95 40 1976 1995 20 60 β β 40 chloramphenicol tetracycline
Antibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
Best Antimicrobials for Staphylococcus aureus Bacteremia
Best Antimicrobials for Staphylococcus aureus Bacteremia I. Methicillin Susceptible Staph aureus (MSSA) A. In vitro - Anti-Staphylococcal β-lactams (Oxacillin, Nafcillin, Cefazolin) are more active B.
Antimicrobials Update
Antimicrobials Update Rosie Amini, PharmD. BCPS Antimicrobial Stewardship Program Coordinator Swedish Medical Center Disclosures: Dr. Amini has no significant financial interest in any of the products
ANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
Antimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
Antimicrobial agents. are chemicals active against microorganisms
Antimicrobial agents are chemicals active against microorganisms Antibacterial Agents Are chemicals active against bacteria Antimicrobials Antibacterial Antifungal Antiviral Antiparasitic: -anti protozoan
number Done by Corrected by Doctor Dr Hamed Al-Zoubi
number 8 Done by Corrected by Doctor Dr Hamed Al-Zoubi 25 10/10/2017 Antibacterial therapy 2 د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy Figure 2/ Antibiotics target Inhibition of microbial
Updates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin
Updates on the Management of Hospital Acquired Infections and Resistant Organisms
Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November
Novel therapies & the role of early switch and early discharge protocols for management of MRSA infections
Novel therapies & the role of early switch and early discharge protocols for management of MRSA infections Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology & Centre for Clinical Pharmacy Louvain
New Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
Should we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
The role of new antibiotics in the treatment of severe infections: Safety and efficacy features
The role of new antibiotics in the treatment of severe infections Safety and efficacy features Christian Eckmann Hannover, Germany The role of new antibiotics in the treatment of severe infections: Safety
Critical impact of antimicrobial resistance
New Antibiotics Kurt B. Stevenson, MD, MPH Professor of Medicine and Epidemiology Division of Infectious Diseases Department of Internal Medicine The Ohio State University College of Medicine Critical
Received 9 February 2010; returned 3 March 2010; revised 16 April 2010; accepted 18 April 2010
J Antimicrob Chemother ; 65: 7 7 doi:.9/jac/dkq59 Advance Access publication 9 June Intracellular activity of the peptide antibiotic NZ: studies with Staphylococcus aureus and human THP- monocytes, and
Tel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
NEW ANTIBACTERIAL DRUGS. Françoise Van Bambeke, PharmD, PhD
EW ATIBACTERIAL DRUGS Drug pipeline for Gram-positive bacteria Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute Université catholique de Louvain,
Infectious Disease Issues in the Intensive Care Unit
Infectious Disease Issues in the Intensive Care Unit Catherine Liu, M.D. Assistant Clinical Professor Division of Infectious Diseases University of California, San Francisco Overview Emerging antibiotic
Consequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
MID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus
Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding
European Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
Antimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
Antimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
Evolution of antibiotic resistance. October 10, 2005
Evolution of antibiotic resistance October 10, 2005 Causes of death, 2001: USA 6. Population: 6,122,210,000 Deaths: 56,554,000 1. Infectious and parasitic diseases: 14.9 million 1. 2. 3. 4. 5. 2. Heart
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
How to translate an antibiogram into a treatment: Gram+ organisms. Dr Y. Van Laethem Department of Infectious Diseases CHU St-Pierre - Brussels
How to translate an antibiogram into a treatment: Gram+ organisms Dr Y. Van Laethem Department of Infectious Diseases CHU St-Pierre - Brussels Streptococci S. pyogenes S. agalactiae (Strepto B) always
Animal models and PK/PD. Examples with selected antibiotics
Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh
In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative
Journal of Antimicrobial Chemotherapy (2008) 62, 116 121 doi:10.1093/jac/dkn124 Advance Access publication 19 April 2008 In vitro activity of telavancin against recent Gram-positive clinical isolates:
Antibacterials. Recent data on linezolid and daptomycin
Antibacterials Recent data on linezolid and daptomycin Patricia Muñoz, MD. Ph.D. (pmunoz@micro.hggm.es) Hospital General Universitario Gregorio Marañón Universidad Complutense de Madrid. 1 GESITRA Reasons
GORILLACILLINS IN THE ICU:
Conflicts of Interest None to declare GORILLACILLINS IN THE ICU: From SPACE and Beyond... Tim T.Y. Lau, PharmD, FCSHP Clinical Pharmacy Specialist in Infectious Diseases Pharmaceutical Sciences, Vancouver
Introduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy
Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Leonardo Pagani MD Director Unit for Hospital Antimicrobial Chemotherapy
Ceftaroline: a new antibiotic for your patients?
Ceftaroline: a new antibiotic for your patients? Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Louvain Drug Research Institute Université catholique de Louvain Brussels, Belgium 11 February
Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi
Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What
RESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
EUCAST Expert Rules for Staphylococcus spp IF resistant to isoxazolylpenicillins
EUAST Expert Rules for 2018 Organisms Agents tested Agents affected Rule aureus Oxacillin efoxitin (disk diffusion), detection of meca or mec gene or of PBP2a All β-lactams except those specifically licensed
Lefamulin: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM
: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM Department of Critical Care, University Hospital ATTIKON National and Kapodistrian University of Athens, Medical School
Discussion Points. Decisions in Selecting Antibiotics
Antibiotics in Acute Care Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical
Antimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased
PK/PD to fight resistance
PK/PD to fight resistance Eradicate Abnormal bacteria Mutations Efflux pumps Mutation-Preventing Concentration Breakpoint values for T > MIC and in practice With the support of Wallonie-Bruxelles-International
European Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
Selective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
Mechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
Skin and Soft Tissue Infections Emerging Therapies and 5 things to know
2011 MFMER slide-1 Skin and Soft Tissue Infections Emerging Therapies and 5 things to know Aaron Tande, MD Assistant Professor of Medicine October 27, 2017 Division of INFECTIOUS DISEASES 2011 MFMER slide-2
MICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut
Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance
Antimicrobial Resistance in the Intensive Care Unit: Mechanisms, Epidemiology, and Management of Specific Resistant Pathogens
Antimicrobial Resistance in the Intensive Care Unit: Mechanisms, Epidemiology, and Management of Specific Resistant Pathogens Henry S. Fraimow, MD a, *, Constantine Tsigrelis, MD b KEYWORDS Resistance
Antibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
Antibiotic Use in the Emergency Department
Antibiotic Use in the Emergency Department Fredrick M. Abrahamian, D.O., FACEP Associate Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA
CO-ACTION. Prof.dr. J.W. Mouton. Note : some technical and all results slides were removed. JPIAMR JWM Paris JWM Paris 2017
CO-ACTION Prof.dr. J.W. Mouton Note : some technical and all results slides were removed JPIAMR 1 Clinical Development of (old drug) combinations : essentials Potency of combination CoAction PK profiling
2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
What s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
Routine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
STAPHYLOCOCCI: KEY AST CHALLENGES
Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu STAPHYLOCOCCI: KEY AST CHALLENGES THE CHALLENGES detection of penicillin resistance detection
In vitro Activity Evaluation of Telavancin against a Contemporary Worldwide Collection of Staphylococcus. aureus. Rodrigo E. Mendes, Ph.D.
AAC Accepts, published online ahead of print on 12 April 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00301-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
MRSA ventilatorassociated
MRSA ventilatorassociated pneumonia Jean Chastre, M.D. www.reamedpitie.com Conflicts of interest Consulting or lecture fees: Medimmune/Astrazeneca, Bayer, Pfizer, Arsanis, Cubist/Merck, Basilea, Aridis,
Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
Antibiotic-Resistant Bugs in the 21st Century A Clinical Super-Challenge. n engl j med 360;5 nejm.org january 29, 2009
Universal Health Insurance Coverage or Economic Relief A False Choice tain financial limits will be required to ensure ongoing health care for all is key to developing the consensus necessary for cost
Introduction to Antimicrobials. Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail.
Introduction to Antimicrobials Rachel J. Gordon, MD, MPH Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail. Major Learning Objectives: 1) Learn the different
Role of IV Therapy in Bone and Joint Infection
Role of IV Therapy in Bone and Joint Infection Andrew Seaton ID Consultant, Queen Elizabeth University Hospital Lead Doctor Antimicrobial Management Team, NHS GGC @raseaton66 OPAT The IVnOAT Perspective
Enterococcal PJI. Miquel Ekkelenkamp
Enterococcal PJI Miquel Ekkelenkamp Enterococci: Gram-positive and round Formerly streptococci (but really quite different) Main clinical species : E. faecalis and E. faecium Mostly opportunistic pathogen
WHY IS THIS IMPORTANT?
CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change
Test results: characterising the antimicrobial activity of daptomycin B. Wiedemann
REVIEW Test results: characterising the antimicrobial activity of daptomycin B. Wiedemann University of Bonn, Bonn, Germany ABSTRACT Daptomycin is the first in a new class of antibiotics, the cyclic lipopeptides.
Empiric therapy for severe suspected Staphylococcus aureus infection
Empiric therapy for severe suspected Staphylococcus aureus infection Salman Qureshi, MD McGill University Faculty of Medicine Department of Critical Care Medicine McGill University Health Centre Relevant
Infectious Disease: Drug Resistance Pattern in New Mexico
Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?
SESSION XVI NEW ANTIBIOTICS
SESSION XVI NEW ANTIBIOTICS New Antibiotics to Treat Anaerobic Infections 2 Goldstein, E.J.C.;* Citron, D.M. Antibiotic Pharmacodynamics 3 Stein, G.E.* Targeting Selenium Metabolism in Stickland Fermentors:
MRSA across roads: new antibiotic options
MRSA across roads: new antibiotic options Javier Garau, MD, PhD University of Barcelona 18th Infection and Sepsis Symposium, BUGS, MUGS AND DRUGS, Porto, 27th February 2013 DISCLOSURES I have accepted
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
A Norazah, M D*, V K E Lim, FRCPath**, MY Rohani, MPath*, A G M Kamel, MD**,
I ORIGINAL ARTICLE In-Vitro Activity of Quinupristin/ Dalfopristin, Levofloxacin and Moxifloxacin Against Fusidic Acid and Rifampicin-Resistant Strains of Methicillin Resistant Staphylococcus Aureus (MRSA)
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
MRSA What Are Our Treatment Options and How Do We Choose the Right One?
MRSA What Are Our Treatment Options and How Do We Choose the Right One? Kristi Traugott, PharmD, BCPS Clinical Pharmacy Specialist Infectious Diseases University Health System San Antonio, TX October 25,
Principles of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
Background and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections
Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg
Antimicrobials. Antimicrobials
Antimicrobials For more than 50 years, antibiotics have come to the rescue by routinely producing rapid and long-lasting miracle cures. However, from the beginning antibiotics have selected for resistance
Antimicrobials & Resistance
Antimicrobials & Resistance History 1908, Paul Ehrlich - Arsenic compound Arsphenamine 1929, Alexander Fleming - Discovery of Penicillin 1935, Gerhard Domag - Discovery of the red dye Prontosil (sulfonamide)
Current challenges in treating MRSA: what are the options?
Current challenges in treating MRSA: what are the options? Expert Rev. Anti Infect. Ther. 6(5), 601 618 (2008) Natasha VDV Ratnaraja and Peter M Hawkey Author for correspondence Regional HPA Microbiology
Management of Antibiotic Resistant Pathogens
Management of Antibiotic Resistant Pathogens Jonathan J. Juliano, MD, MSPH Assistant Professor UNC School of Medicine Director of Antibiotic Stewardship UNC Hospitals, Chapel Hill SPICE Conference Friday
2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
Optimisation of therapy in Gram-negative infections: TEMOCILLIN
ESCMID Conference on Reviving ld Antibiotics ptimisation of therapy in Gram-negative infections: TEMCILLIN Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
Bacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
ESCMID Online Lecture Library. by author
ESCMID Postgraduate Technical Workshop Antimicrobial susceptibility testing and surveillance of resistance in Gram-positive cocci: laboratory to clinic Current epidemiology of invasive enterococci in Europe
Antibiotic resistance a mechanistic overview Neil Woodford
Antibiotic Resistance a Mechanistic verview BSc PhD FRCPath Consultant Clinical Scientist 1 Polymyxin Colistin Daptomycin Mechanisms of antibiotic action Quinolones Mupirocin Nitrofurans Nitroimidazoles
Antibiotics and Stewardship: What s New in Pediatrics-Land?
Antibiotics and Stewardship: What s New in Pediatrics-Land? Sean P. Elliott, MD Professor of Pediatrics Associate Chair of Education, Department of Pediatrics University of Arizona College of Medicine
مادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs: